Physician profile
Govind Singh
NPI 1730199464
$959.05
in general payments reported to CMS, 2019-2025
19 companies · $188 in 2025
The $188 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $725 · 2024: $46.59 · 2025: $188.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $235.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $234.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $141.64 | 2019-2024 | |
| Novo Nordisk INC | $138.27 | 2019-2025 | Rybelsus, Ozempic |
| Amgen INC. | $128.09 | 2019-2025 | Evenity |
| Janssen Pharmaceuticals, INC | $94.28 | 2019 | |
| Glaxosmithkline, LLC. | $69.50 | 2019-2025 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.42 | 2019 | |
| Novartis Pharmaceuticals Corporation | $43.75 | 2019 | |
| Ferring Pharmaceuticals INC. | $40.32 | 2019 | |
| Astellas Pharma US INC | $36.55 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $35.14 | 2019 | |
| Lilly USA, LLC | $26.31 | 2025 | Zepbound, Mounjaro |
| Regeneron Healthcare Solutions, INC. | $22.18 | 2024 | Dupixent |
| Merck Sharp & Dohme LLC | $22.05 | 2019 | |
| Abbvie INC. | $21.42 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.02 | 2025 | Caplyta |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $19.64 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $16.84 | 2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $16.13 | 2019 | |
| Therapeuticsmd, INC. | $15.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Govind Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.